60 Degrees Pharmaceuticals, Inc.
SXTP
$1.75
-$0.11-5.91%
| Weiss Ratings | SXTP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | SXTP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | SXTP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | SXTP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 10.06% | |||
| 30-Day Total Return | -66.98% | |||
| 60-Day Total Return | -78.79% | |||
| 90-Day Total Return | -57.47% | |||
| Year to Date Total Return | -73.28% | |||
| 1-Year Total Return | -88.96% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -94.83% | |||
| 52-Week Low % Change | 31.91% | |||
| Price | SXTP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $35.99 | |||
| 52-Week Low Price | $1.41 | |||
| 52-Week Low Price (Date) | Mar 10, 2025 | |||
| 52-Week High Price (Date) | Jul 19, 2024 | |||
| Valuation | SXTP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.74M | |||
| Enterprise Value | 7.37M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -43.69 | |||
| Earnings Per Share Growth | -70.57% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.96 | |||
| Price/Book (Q) | -0.20 | |||
| Enterprise Value/Revenue (TTM) | 15.94 | |||
| Price | $1.75 | |||
| Enterprise Value/EBITDA (TTM) | -0.78 | |||
| Enterprise Value/EBIT | -0.77 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | SXTP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 488.60K | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | SXTP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 202 327 5422 | |||
| Address | 1025 Connecticut Avenue NW Washington, DC 20036 | |||
| Website | www.60degreespharma.com | |||
| Country | United States | |||
| Year Founded | 2010 | |||
| Profitability | SXTP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -2,060.83% | |||
| Profit Margin | -1,710.85% | |||
| Management Effectiveness | SXTP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -71.91% | |||
| Return on Equity | -- | |||
| Income Statement | SXTP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 462.60K | |||
| Total Revenue (TTM) | 462.60K | |||
| Revenue Per Share | $0.95 | |||
| Gross Profit (TTM) | -4.42M | |||
| EBITDA (TTM) | -9.49M | |||
| EBIT (TTM) | -9.53M | |||
| Net Income (TTM) | -7.91M | |||
| Net Income Avl. to Common (TTM) | -7.91M | |||
| Total Revenue Growth (Q YOY) | 16.80% | |||
| Earnings Growth (Q YOY) | -151.77% | |||
| EPS Diluted (TTM) | -43.69 | |||
| EPS Diluted Growth (Q YOY) | -110.23% | |||
| Balance Sheet | SXTP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 5.01M | |||
| Cash Per Share (Q) | $10.26 | |||
| Total Current Assets (Q) | 6.89M | |||
| Total Preferred Equity (Q) | 9.57 | |||
| Total Equity (Q) | 5.96M | |||
| Current Ratio (Q) | 5.260 | |||
| Book Value Per Share (Q) | -$9.47 | |||
| Total Assets (Q) | 7.42M | |||
| Total Current Liabilities (Q) | 1.31M | |||
| Total Debt (Q) | 156.70K | |||
| Total Liabilities (Q) | 1.46M | |||
| Total Common Equity (Q) | -3.53M | |||
| Cash Flow | SXTP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.95M | |||
| Cash from Financing (TTM) | 7.05M | |||
| Net Change in Cash (TTM) | 1.08M | |||
| Levered Free Cash Flow (TTM) | 1.44M | |||
| Cash from Operations (TTM) | -4.07M | |||
